NCT05393713View on ClinicalTrials.gov

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8MelanomaMetastatic MelanomaRecurrent Metastatic Melanoma
Interventions
BIOLOGICAL

Anti-PD-L1 Monoclonal Antibody IMC-001

Given intra-lymphatically via DoseConnect device

PROCEDURE

Punch Biopsy

Undergo punch biopsy

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05393713 - Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study | Biotech Hunter | Biotech Hunter